Anterior|Siguiente

Progreso de la investigación sobre el tratamiento del carcinoma hepatocelular con medicina tradicional china basado en la vía de señalización NF-κB

  • role： First author第一作者
  • Affiliation：

    Henan University of Chinese Medicine，Zhengzhou 450046，China

  • Email：1350355659@qq.com
  • Introduction：杨韧，在读硕士，从事中医药防治肝胆脾胃病的研究，E-mail：1350355659@qq.com
YANG Ren1,  
  • Affiliation：

    Henan Province Hospital of Traditional Chinese Medicine，Zhengzhou 450002，China

LI Mengge2,  
  • Affiliation：

    Henan Province Hospital of Traditional Chinese Medicine，Zhengzhou 450002，China

DANG Zhibo2,  
  • Affiliation：

    Henan University of Chinese Medicine，Zhengzhou 450046，China

GUO Biaobiao1,  
  • Affiliation：

    Henan University of Chinese Medicine，Zhengzhou 450046，China

LIU Shilong1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Henan Province Hospital of Traditional Chinese Medicine，Zhengzhou 450002，China

  • Email：dzhqn@126.com
  • Introduction：党中勤，主任医师，博士生导师，从事中西医结合治疗肝胆脾胃疾病的研究，E-mail：dzhqn@126.com
DANG Zhongqin2*

resumen

El carcinoma hepatocelular (CHC), como el subtipo principal del cáncer hepático primario, ocupa un lugar destacado en la incidencia y la mortalidad de tumores malignos en nuestro país. Los síntomas en etapas tempranas pueden ser poco evidentes, el pronóstico clínico es desfavorable, la tasa de supervivencia de los pacientes es baja, siendo una enfermedad que representa una amenaza grave para la salud pública. Su aparición está relacionada con la infección por virus de la hepatitis, consumo de alcohol, obesidad, daño por medicamentos, trastornos inmunitarios y otros factores múltiples que pueden combinarse para causar la enfermedad. Actualmente, los métodos comunes en la medicina moderna para tratar el CHC incluyen la resección quirúrgica, el trasplante de hígado, la ablación por radiofrecuencia, la radioterapia y la quimioterapia, pero todos presentan ciertas limitaciones, como efectos adversos significativos y mal pronóstico, lo que supone una gran carga psicológica y económica para los pacientes. La medicina tradicional china (MTC) tiene una larga historia en el tratamiento del cáncer de hígado, con ventajas como múltiples objetivos, múltiples niveles, pocos efectos adversos y baja tasa de recurrencia; no solo puede mejorar la eficacia terapéutica, sino también aliviar los efectos secundarios de la radioterapia, la quimioterapia y la cirugía, ganando así una amplia atención. Numerosos estudios han demostrado que la MTC tiene efectos antitumorales, antiinflamatorios y antioxidantes, cuyo mecanismo podría estar relacionado con la regulación de la vía de señalización del factor nuclear de transcripción-κB (NF-κB), que influye en varias etapas de la carcinogénesis hepática, como la proliferación celular, la invasión, la metástasis y la apoptosis. El mecanismo de acción de la vía de señalización NF-κB en el tratamiento del CHC con MTC se ha convertido en una importante dirección de investigación oncológica actual. Basándose en la literatura existente, se utilizó un método de revisión sistemática para buscar y analizar literatura relevante reciente en chino y en inglés. Integrando los mecanismos moleculares de regulación de la vía de señalización NF-κB y su papel clave en el desarrollo del CHC, se puede profundizar en los avances más recientes en la intervención de la MTC en esta vía para el tratamiento del CHC, lo que ayuda a proporcionar una nueva base teórica y un pensamiento de transformación clínica para la prevención y el tratamiento del CHC con MTC.

palabra clave

factor nuclear de transcripción-κB (NF-κB); vía de señalización; carcinoma hepatocelular; medicina tradicional china; progreso de la investigación

References

  1. 1.
    Department of Medical Administration，National Health Commission of the People's Republic of China.Guideline for diagnosis and treatment of primary liver cancer （2024 edition）［J］.Chin J Magn Reson Imaging，2024，15（6）：1-18.
  2. 2.
    BRAY F，LAVERSANNE M，SUNG H，et al.Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2024，74（3）：229-263.
  3. 3.
    JA M，LM K，CB S，et al.Diagnosis，staging，and management of hepatocellular carcinoma：2018 practice guidance by the American association for the study of liver diseases［J］.Hepatology，2018，68（2）：723-750.
  4. 4.
    ZHOU J，SUN H，WANG Z，et al.Guidelines for the diagnosis and treatment of hepatocellular carcinoma （2019 edition）［J］.Liver Cancer，2020，9（6）：682-720.
  5. 5.
    YE S W，ZAHANG W.Professor ZHANG Wei's diagnostic and therapeutic approach for primary liver cancer［J］.Chin J Integr Tradit West Med Liver Dis，2023，33（2）：160-162.
  6. 6.
    CASADEI-GARDINI A，SCARTOZZI M，TADA T，et al.Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma：An inverse probability of treatment weighting analysis［J］.Liver Int，2021，41（6）：1389-1397.
  7. 7.
    SEN R，BALTIMORE D.Inducibility of kappa immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism［J］.Cell，1986，47（6）：921-928.
  8. 8.
    WAN F，LENARDO M J.The nuclear signaling of NF-κB：Current knowledge，new insights，and future perspectives［J］.Cell Res，2010，20（1）：24-33.
  9. 9.
    CUI Y，CAO X P.Research advances in nuclear factor-κB［J］.J North Sichuan Med Coll，2014，29（5）：510-513.
  10. 10.
    LI M，LIU P，WANG B，et al.Inhibition of nuclear factor kappa B as a therapeutic target for lung cancer［J］.Altern Ther Health Med，2022，28（1）：44-51.
  11. 11.
    LIU Z，WU F G，ZOU J T，et al.Correlation between nuclear factor-kappa B and bone metastasis of lung cancer［J］.Pract J Cancer，2021，36（12）：1950-1952.
  12. 12.
    GENG X，CHI W C，LIN X Y，et al.Mechanism of NF-κB signaling pathway in regulating lung cancer and intervention of traditional Chinese medicine：A review［J］.Chin J Exp Tradit Med Form，2023，29（16）：207-216.
  13. 13.
    MULERO M C，HUXFORD T，GHOSH G.NF-κB，IκB，and IKK：Integral components of immune system signaling［J］.Adv Exp Med Biol，2019，1172：207-226.
  14. 14.
    PERKINS N D.The diverse and complex roles of NF-κB subunits in cancer［J］.Nat Rev Cancer，2012，12（2）：121-132.
  15. 15.
    DURAND J K，ZHANG Q，BALDWIN A S.Roles for the IKK-related kinases TBK1 and IKKε in cancer［J］.Cells，2018，7（9）：139.
  16. 16.
    WEN J，HUANG Z，WEI Y，et al.Hsa-microRNA-27b-3p inhibits hepatocellular carcinoma progression by inactivating transforming growth factor-activated kinase-binding protein 3/nuclear factor kappa B signalling［J］.Cell Mol Biol Lett，2022，27（1）：79.
  17. 17.
    LI H P，DAI A J，LI Y H，et al.Expression of nuclear factor-κB and nucleolar protein 14 in primary hepatocellular carcinoma and their relationship with clinical characteristics［J］.Oncol Prog，2022，20（10）：1028-1030，1034.
  18. 18.
    RAPE M.Ubiquitylation at the crossroads of development and disease［J］.Nat Rev Mol Cell Biol，2018，19（1）：59-70.
  19. 19.
    YU H，LIN L，ZHANG Z，et al.Targeting NF-κB pathway for the therapy of diseases：Mechanism and clinical study［J］.Signal Transduct Target Ther，2020，5（1）：209.
  20. 20.
    SHENG X，YOU Q，ZHU H，et al.Enterohemorrhagic E.coli effector NleL disrupts host NF-κB signaling by targeting multiple host proteins［J］.J Mol Cell Biol，2020，12（4）：318-321.
  21. 21.
    SENFTLEBEN U，CAO Y，XIAO G，et al.Activation by IKKalpha of a second，evolutionary conserved，NF-kappa B signaling pathway［J］.Science，2001，293（5534）：1495-1499.
  22. 22.
    VALLABHAPURAPU S，KARIN M.Regulation and function of NF-kappaB transcription factors in the immune system［J］.Annu Rev Immunol，2009，27：693-733.
  23. 23.
    SU L J，REN Y C，CHEN Z，et al.Ginsenoside Rb1 improves brain，lung，and intestinal barrier damage in middle cerebral artery occlusion/reperfusion （MCAO/R） micevia the PPARγ signaling pathway［J］.Chin J Nat Med，2022，20（8）：561-571.
  24. 24.
    HARHAJ E W，DIXIT V M.Deubiquitinases in the regulation of NF-κB signaling［J］.Cell Res，2011，21（1）：22-39.
  25. 25.
    KEARNS J D，BASAK S，WERNER S L，et al.Ikappa Bepsilon provides negative feedback to control NF-kappaB oscillations，signaling dynamics，and inflammatory gene expression［J］.J Cell Biol，2006，173（5）：659-664.
  26. 26.
    SHEMBADE N，HARHAJ N S，PARVATIYAR K，et al.The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20［J］.Nat Immunol，2008，9（3）：254-262.
  27. 27.
    HYMOWITZ S G，WERTZ I E.A20：From ubiquitin editing to tumour suppression［J］.Nat Rev Cancer，2010，10（5）：332-341.
  28. 28.
    HITOTSUMATSU O，AHMAD R C，TAVARES R，et al.The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals［J］.Immunity，2008，28（3）：381-390.
  29. 29.
    XIA G，QI F，YANG J H，et al.Expression of nuclear factor-kappa B p65 in hepatocellular carcinoma and its significance［J］.Clin J Clin Hepatol，2017，33（12）：2342-2345.
  30. 30.
    CHIANG I T，LIU Y C，WANG W H，et al.Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells［J］.In Vivo，2012，26（4）：671-681.
  31. 31.
    LI J B，KE S D，HU S M.Effect of berberine on TNF-α-induced VEGF expression via NF-κB signaling pathway［J］.J Huazhong Univ Sci Technol Med Sci，2014，43（4）：386-390.
  32. 32.
    GRETEN F R，GRIVENNIKOV S I.Inflammation and Cancer：Triggers，mechanisms，and consequences［J］.Immunity，2019，51（1）：27-41.
  33. 33.
    O’NEIL B H，BŮZKOVÁ P，FARRAH H，et al.Expression of nuclear factor-kappa B family proteins in hepatocellular carcinomas［J］.Oncology，2007，72（1-2）：97-104.
  34. 34.
    XIA Y H，ZHOU J，CHANG Y H，et al.Expression of NF-κB and Caspase-3 and its significance in hepatocellular carcinomas［J］.China J Mod Med，2012，22（3）：26-29.
  35. 35.
    YANG Z H，ZHANG Y，LIU H J，et al.Research progress of the role of NF-κB in invasion and metastasis of primary hepatocellular carcinoma［J］.Clin Res Pract，2018，3（31）：197-198.
  36. 36.
    WANG Z，YING Y M，LI K Q，et al.Marsdeniae tenacissima extract-induced growth inhibition and apoptosis in hepatoma carcinoma cells is mediated through the p53/nuclear factor-κB signaling pathway［J］.Exp Ther Med，2017，14（3）：2477-2484.
  37. 37.
    JIANG J X，LI N，KANG R X，et al.Study on the improvement of tumor inflammation in H22 mice with hepatocellular carcinoma through IL-6/STAT3/NF-κB sgnaling pathway in the total saponins from Marsdenia Tenacissima［J］.J Liaoning Univ Tradit Chin Med，2024，26（11）：30-35.
  38. 38.
    LI M，JIANG C Z，CHEN J T，et al.Formononetin inhibits tumor immune escape of hepatocarcinoma-bearing mice through TLR4/NF-κB pathway［J］.Chin J Immunol，2023，39（9）：1872-1877.
  39. 39.
    OU S，LIU W L，DENG X J.Acute and chronic toxicity studies of wild Asian ginseng fruit extract［J］.Strait Pharm J，2019，31（6）：19-23.
  40. 40.
    LI Y，LI H M，QI Y，et al.Exploring the anti-hepatoma effect of fermentation liquor of fresh fruit of Phytolacca acinosa Roxb.in vitro based on PI3K/Akt/NF-κB signaling pathway［J］.Chin J Mod Appl Pharm，2025，42（5）：697-705.
  41. 41.
    WANG B，WANG H，ZHAO Q，et al.Matrine induces hepatocellular carcinoma apoptosis and represses EMT and stemness through microRNA-299-3p/PGAM1 axis［J］.Growth Factors，2022，40（5-6）：200-211.
  42. 42.
    WANG W，LI M，SI H，et al.Network pharmacology and integrated molecular docking study on the mechanism of the therapeutic effect of Fangfeng decoction in osteoarthritis［J］.Curr Pharm Des，2023，29（5）：379-392.
  43. 43.
    XIE W Y，LU Y B，GUO X M，et al.Exploring the mechanism of Sophora Flavescens mediated NF-κB pathway against hepatocellular based on target network and molecular docking［J］.Heilongjiang Med J，2024，37（4）：745-750.
  44. 44.
    FAN Y，XUE H，ZHENG H.Systemic therapy for hepatocellular carcinoma：Current updates and outlook［J］.J Hepatocell Carcinoma，2022，30（9）：233-263.
  45. 45.
    FENG Q Z.Baicalein combined with luteolin against liver cancer by inhibiting the EGFR/ERK/NF-κB signaling pathway［D］.Hefei：Anhui Medical University，2024.
  46. 46.
    XIE X，XIE S，XIE C，et al.Pristimerin attenuates cell proliferation of uveal melanoma cells by inhibiting insulin-like growth factor-1 receptor and its downstream pathways［J］.J Cell Mol Med，2019，23（11）：7545-7553.
  47. 47.
    FU L N，XING B Z，CHEN Y，et al.Influence of pristimerin on autophagy and apoptosis in hepatocellular carcinoma cells by regulating Akt/NF-κB/mTOR signaling pathway［J］.Chin J Anat，2024，47（5）：404-409.
  48. 48.
    LI C，DU L M，SUN Q，et al.The effect of atractylodes macrocephalaon polysaccharide on stem cell-like properties of hepatoma cells，epithelial-mesenchymal transition and phosphorylation of Akt/NF-κB pathway［J］.Chin Clin Oncol，2024，29（8）：735-739.
  49. 49.
    ZHANG X，LI J M，YANG F F，et al.The effect of hydroxysafflor yellow A on NF-κB signaling pathway in transplanted hepatocellula carcinoma in mice［J］.J Binzhou Med Coll，2016，39（2）：89-91，95.
  50. 50.
    CHANG C，ZHU Y Q，MEI J J，et al.Involvement of mitochondrial pathway in NCTD-induced cytotoxicity in human HepG2 cells［J］.J Exp Clin Cancer Res，2010，29（1）：145.
  51. 51.
    WANG D.The role of nuclear factor-kappa B in the norcantharidininduced apoptosis of liver cancer cell SMMC-7721［D］.Shijiazhuang：Hebei Medical University，2013.
  52. 52.
    HU J X，XI X T，WANG X M，et al.Mechanism of Humifuse euphorbia in regulating tumor angiogenesis by NF-κB / VEGF signal pathway［J］.Chin J Exp Tradit Med Form，2018，24（23）：165-170.
  53. 53.
    HU Q，ZHU D Y，TAN X M，et al.Effect of drug-containing serum of Clerodendrum bungei on liver cancer cells through PI3K/Akt signaling pathway［J］.Chin J Exp Tradit Med Form，2019，25（22）：28-33.
  54. 54.
    WANG C L，WEN X D.Transcriptome analysis of ethanol extract of Akebia trifoliate （Thunb.） Koidz on cell proliferation inhibitory functions and apoptosis promotion in human liver cells［J］.Chin J Comp Med，2024，34（8）：60-71.
  55. 55.
    WANG R，SHAO X，YANG J，et al.Ginkgo biloba extract mechanism inhibits hepatocellular carcinoma through the nuclear factor-κB/p53 signaling pathway［J］.J Environ Pathol Toxicol Oncol，2020，39（2）：179-189.
  56. 56.
    DUAN Y F，ZHANG Z R，FAN J L，et al.Studies on the effects of Ginsenosides Rh2 and CK on the malignant behavior of ovarian cancer cells and on ovarian cancer cell-macrophage crosstalk［J］.J Chin Med Pharmacol，2024，52（12）：18-24.
  57. 57.
    ZHANG J，MA X，FAN D.Ginsenoside CK inhibits hypoxia-induced epithelial-mesenchymal transformation through the HIF-1α/NF-κB feedback pathway in hepatocellular carcinoma［J］.Foods，2021，10（6）：1195.
  58. 58.
    LI M，ZHANG M，ZHANG Z L，et al.Induction of apoptosis by berberine in hepatocellular carcinoma HepG2 cells via downregulation of NF-κB［J］.Oncol Res，2017，25（2）：233-239.
  59. 59.
    YAO F，ZHANG L，JIANG G，et al.Osthole attenuates angiogenesis in an orthotopic mouse model of hepatocellular carcinoma via the downregulation of nuclear factor-κB and vascular endothelial growth factor［J］.Oncol Lett，2018，16（4）：4471-4479.
  60. 60.
    ZHAO X，ZHAO P J，GAO J L，et al.Protective effects of Fuzheng Huajie decoction on liver tissues in a rat model of diethylnitrosamine-induced hepatocellular carcinoma［J］.Zhejiang J Integr Tradit Chin West Med，2023，33（4）：313-317.
  61. 61.
    DU F，DONG L J.Mechanism of Astragalus polysaccharide in inhibiting proliferation of human hepatocellular carcinoma cells［J］.West China J Pharm Sci，2020，35（4）：402-406.
  62. 62.
    CHEN C，ZHANG J F，FANG X.The study on mechanism of action of Herba Hedyotis diffusae in treating liver-cancer［J］.Henan Tradit Chin Med，2018，38（1）：67-71.
  63. 63.
    YANG P W，ZHU J X，CHEN X J，et al.Mechanism of Scutellariae Barbatae Herba and Hedyotis diffusa Willd.regulating Wnt/β-catenin axis［J］.Pharmacol Clin Chin Mater Med，2024，40（12）：48-54.
  64. 64.
    YANG J W，ZHANG Y.Research progress on anti-tumor effect of extracted parts and active components of Ranunculus ternatus［J］.Drug Eval Res，2021，44（2）：446-451.
  65. 65.
    WANG B，CHENG Y F，WU J，et al.Effects of polysaccharides from roots of Radix Tetrastigma on proliferation，apoptosis，migration and invasion of HepG2 cells［J］.J Jinan Univ：Nat Sci Med Ed，2020，41（5）：444-454.
  66. 66.
    YANG Y P，DUAN Y Q，LIANG J Q，et al.Investigation of the tumor suppression effect and immune function of Shenqi Yiliu Decoction combined with Cisplatin on H22 liver cancer tumor-bearing mice based on HMGB1/TLR4/NF-κB pathway［J］.Mod Tradit Chin Med Mater Med World Sci Technol，2023，25（7）：2365-2372.
  67. 67.
    ZENG Q T，MA C L，LI H L，et al.Inhibitory effect of Shenqi Yiliu decoction combined with Cisplatin on H22 tumor-bearing mice and its impact on immune function［J］.Gansu Sci and Technol，2018，34（6）：127-130.
  68. 68.
    HUANG C L，LIU H Z.Effect of Shenqi Yiliu decoction combined with neoadjuvant chemotherapy on immune function and prognosis［J］.China Contemp Med，2021，27（17）：139-140.
  69. 69.
    SUN J L，WEN B，YANG X M，et al.Mechanism research of regulation of proliferation and metastasis of hepatoma cells Hep3B by Biejiajian pill based on PI3K/Akt/GSK-3β signaling pathway［J］.China J Tradit Chin Med Pharm，2021，36（3）：1361-1365.
  70. 70.
    ZHONG X D.Mechanism of Biejia Jian wan regulating epithelial-mesenchymal transition of hepatocellular carcinoma cells through the NF-κB signaling pathway［D］.Guangzhou：Southern Medical University，2022.
  71. 71.
    CHEN Y，HU H，ZHANG S J，et al.Effect of the Sijunzi decoction on the T lymphocyte and NK cell of the hepatocellular［J］.Chin J Integr Tradit West Med Liver Dis，2017，27（1）：8-10.
  72. 72.
    DE QUEIROZ R M，CARVALHO E，DIAS W B.O-GlcNAcylation：The sweet side of the cancer［J］.Frontiers in Oncology，2014，4：132.
  73. 73.
    LI M Z，FANG Z Q，ZHANG W F，et al.Mechanism of Si Junzitang in inhibiting hepatocellular carcinoma progression through regulating O-GlcNAcylation of NF-κB p65 in paracancerous tissues［J］.Chin J Exp Tradit Med Form，2024，30（15）：21-28.

Leer el texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website